Home > Cardiology > AHA 2020 > Miscellaneous > Sotatercept: potential new treatment option for PAH

Sotatercept: potential new treatment option for PAH

Presented By
Prof. Vallerie McLaughlin, University of Michigan, USA
AHA 2020
Phase 2, PULSAR

Sotatercept improved right ventricular-pulmonary arterial (RV-PA) coupling and RV function in patients with pulmonary arterial hypertension (PAH). This was shown by new cardiac and pulmonary function data from the ongoing phase 2 PULSAR trial of sotatercept [1]. This abstract won the AHA’s “Cardiopulmonary Best Abstract” award.

Sotatercept is a novel investigatory agent designed to be a selective ligand trap for members of the transforming growth factor (TGF)-β superfamily to reset signalling cascades that drive PAH. PULSAR (NCT03496207) is an ongoing, double-blind, placebo-controlled study in which PAH patients (mean age 48 years) were randomised in a 3:3:4 ratio to receive placebo, sotatercept 0.3 mg/kg, or sotatercept 0.7 mg/kg subcutaneously every 21 days over a 24-week treatment period, in combination with stable background PAH standard-of-care therapies. The...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on